FDA Approves IND Application for Prodarsan® in Cockayne Syndrome Patients

Pharming Group NV announced today that its wholly-owned subsidiary, DNage, has had its Investigational New Drug (IND) application for Prodarsan® accepted by the FDA. Acting as DNage's US agent, Clinquest filed the IND Application, which contains information on the product's preclinical and clinical results, manufacturing data, and detailed clinical protocols for proposed clinical studies.


 For more information:

Pharming - FDA Approves Investigational New Drug Application For Prodarsan® In Cockayne Syndrome Patients